Medibact GuidesShop at Medibact

Stacking Module

SS-31 Stacking Module

SS-31 (elamipretide) is the mitochondrial compound with the most genuine clinical development history here — it has been through real trials, with mixed results — which makes it unusual in this catalog for having disappointing evidence rather than absent evidence.

SS-31 Guide at MedibactSS-31 calculatorFull stacking guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking SS-31

  • SS-31 is elamipretide, and elamipretide now has a label: Forzinity received accelerated FDA approval on 2025-09-19 for muscle strength in Barth syndrome (patients of at least 30 kg), at 40 mg subcutaneously once daily from an 80 mg/mL vial. Every registered subcutaneous trial read for this site used the same 40 mg, while vendor pages cite 5 to 10 mg for 'SS-31', a figure no label or trial states.
  • The label's 40 mg is 0.5 mL (50 units) of the 80 mg/mL product. Research vials are 5, 10 and 50 mg: only the 50 mg vial reaches 40 mg in one U-100 syringe (1 mL of water, 50 mg/mL, 80 units), and a 5 or 10 mg vial cannot hold that amount at all — which matters when a stack sheet lists SS-31 beside a microgram-scale partner.
  • SS-31 targets cardiolipin on the inner mitochondrial membrane. That is a structural target, distinct from MOTS-c's AMPK signaling, which is why the two are the coherent mitochondrial pairing.
  • It has an actual clinical trial record (developed as elamipretide), including trials that did not meet primary endpoints. Absent evidence and disappointing evidence are different things, and this is the latter.
  • It is not FDA-approved for the uses discussed in research contexts.
  • No controlled trial has studied SS-31 combined with anything.

Combinations in detail

Mitochondrial support

SS-31 + MOTS-c
Why it is proposed
Structural membrane targeting alongside AMPK signaling — two genuinely different approaches to mitochondrial function, which makes this the best-constructed pairing in the mitochondrial group.
What is reported in practice
Reported as separate vials, commonly concurrent.
Cautions specific to this combination
No combination data. SS-31's own trial record is mixed, which should temper expectations for anything built on it.

Cellular-aging stack

SS-31 + NAD+ or Epithalon
Why it is proposed
Combines membrane-targeted mitochondrial support with either NAD+ precursor supply or the Khavinson longevity bioregulator.
What is reported in practice
Community-reported longevity pairings, often in defined courses.
Cautions specific to this combination
NAD+ injection has its own thin evidence base; Epithalon's literature is concentrated in one research tradition. Both pairings are thematic rather than mechanistically specified.

What to avoid, and why

  • Reading elamipretide's clinical development as validation — several trials did not meet primary endpoints, which is information rather than a gap.
  • Combining it with another membrane-targeted mitochondrial compound expecting additive effect; the coherent partner acts through a different mechanism.
  • Treating community dosing as established; approved dosing does not exist.

Related reading

Reported SS-31 doses, sourcedMixing SS-31: water and unitsThe Peptide Stacking GuideBrowse stacks by compound

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.